282 related articles for article (PubMed ID: 37720350)
1. Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer.
Hoskin AJ; Holt AK; Legge DN; Collard TJ; Williams AC; Vincent EE
Explor Target Antitumor Ther; 2023; 4(4):600-615. PubMed ID: 37720350
[TBL] [Abstract][Full Text] [Related]
2. Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition.
Holt AK; Najumudeen AK; Collard TJ; Li H; Millett LM; Hoskin AJ; Legge DN; Mortensson EMH; Flanagan DJ; Jones N; Kollareddy M; Timms P; Hitchings MD; Cronin J; Sansom OJ; Williams AC; Vincent EE
Cancer Metab; 2023 Oct; 11(1):18. PubMed ID: 37858256
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
4. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
6. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus.
Chen J; Stark LA
Biomedicines; 2017 Jul; 5(3):. PubMed ID: 28718829
[TBL] [Abstract][Full Text] [Related]
8. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
9. Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo.
Claudius AK; Kankipati CS; Kilari RS; Hassan S; Guest K; Russell ST; Perry CJ; Stark LA; Nicholl ID
Oncol Rep; 2014 Oct; 32(4):1670-80. PubMed ID: 25109257
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
12. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression.
Tafani M; De Santis E; Coppola L; Perrone GA; Carnevale I; Russo A; Pucci B; Carpi A; Bizzarri M; Russo MA
Biomed Pharmacother; 2014 Feb; 68(1):1-5. PubMed ID: 24286852
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
14. Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells.
Petővári G; Hujber Z; Krencz I; Dankó T; Nagy N; Tóth F; Raffay R; Mészáros K; Rajnai H; Vetlényi E; Takács-Vellai K; Jeney A; Sebestyén A
Cancer Cell Int; 2018; 18():211. PubMed ID: 30574020
[TBL] [Abstract][Full Text] [Related]
15. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy.
Abdel-Wahab AF; Mahmoud W; Al-Harizy RM
Pharmacol Res; 2019 Dec; 150():104511. PubMed ID: 31678210
[TBL] [Abstract][Full Text] [Related]
16. Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection.
Jiang Q; Qiu Y; Kurland IJ; Drlica K; Subbian S; Tyagi S; Shi L
mBio; 2022 Aug; 13(4):e0127422. PubMed ID: 35762591
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Reprogramming in Thyroid Carcinoma.
Coelho RG; Fortunato RS; Carvalho DP
Front Oncol; 2018; 8():82. PubMed ID: 29629339
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Sandler RS
Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
[TBL] [Abstract][Full Text] [Related]
19. Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review.
Belayneh YM; Amare GG; Meharie BG
J Oncol Pharm Pract; 2021 Jun; 27(4):954-961. PubMed ID: 33427041
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Schrör K
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):473-84. PubMed ID: 22122764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
